SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program.

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose SANTA MONICA, Calif., Feb. 08 Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program nalmefene solution in one nostril). Treatment D: 1.5 mg i.m. (1.5 ml of a 1.0-mg/ml nalmefene solution). The IN treatments were randomized while the intramuscular dose was the last treatment of all subjects. The high dose (3 mg) of nalmefene was selected based on the relative bioavailability (∼50%) Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene “The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene,” said Dr. Roger Crystal, President and CEO, Opiant An intranasal formulation of nalmefene, a long-lasting opioid antagonist, designated as OPNT 003, is under development by Opiant Pharmaceuticals, for the Indication Program / Regulatory Pathway Preclinical Phase I Phase II Phase III NDA FDA Approval Partner; Opioid Overdose: NARCAN® Nasal Spray: Approved: Opioid Overdose We have responded to this call, and are developing an intranasal formulation of nalmefene, a more potent, longer acting opioid antagonist that is especially … SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose.

OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the … OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. Study Drugs.

Agreementcombines Opiant’sopioid antagonist OPNT003 nasal nalmefene,with Aptar'sFDA-approved UnitDose System delivery device; Reinforces Opiant’s continued commitment to innovative overdose

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone.; The Phase 1 study in healthy volunteers will evaluate the effectiveness of 3mg nasal nalmefene compared to 4 mg nasal naloxone to reverse the respiratory depression produced 2021-03-09 SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: O OPNT003 nasal nalmefene for opioid overdose - Opiant to use Aptar Pharma’s Unit Dose System- Upcoming FDA meeting in December to review Pharmacodynamic study in … SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 million from the National Institutes of Health’s (“NIH”) National Institute SANTA MONICA - Opiant Pharmaceuticals, Inc. ('Opiant') (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma ('Aptar'), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar's Unit Dose System (UDS) for the treatment of opioid overdose.

2020-12-15

Materials and Narcan maker Opiant Pharmaceuticals has admitted defeat in a mid-stage trial a pivotal trial for OPNT003, a nasal version of nalmefene for opioid overdose; Prior to joining Opiant, Dr. Skolnick served as the Director, Division of heroin and prescription opioids Nalmefene is a potent, long acting opioid antagonist; The latest Tweets from Opiant Pharmaceuticals (@Opiant_Pharma). dosed in study comparing OPNT003, nasal nalmefene, with nasal naloxone $OPNT Opiant Pharmaceuticals Announces First Patient Dosed In Confirmatory Pharmacokinetic Study Assessing Opnt003, Nasal Nalmefene, For The Treatment Of 12 Feb 2021 administered nalmefene.

SANTA MONICA, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced positive data from a Phase I clinical study of its product candidate OPNT003 (intranasal nalmefene), and provided an update on a meeting held February 8, 2018 with the U.S. Food and Drug Administration (FDA) regarding its planned development program. OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be especially useful in treating overdose by high-potency synthetic opioids, such as fentanyl. Study Drugs. Nalmefene hydrochloride (cGMP grade) was purchased from Rusan PharmaLtd.
Vårdhandboken blodtransfusion

The IN treatments were randomized while the intramuscular dose was the last treatment of all subjects. The high dose (3 mg) of nalmefene was selected based on the relative bioavailability (∼50%) SANTA MONICA, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be About OPNT003 OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication OPNT003, nasal nalmefene, is in development as a potent, rapid-onset, long-acting opioid antagonist for the treatment of opioid overdose. OPNT003 is designed as a rescue medication that could be Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene “The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene,” said Dr. Roger Crystal, President and CEO, Opiant “The initiation of this head-to-head study is an important step in our comprehensive development program for OPNT003, nasal nalmefene,” said Dr. Roger Crystal, President and CEO, Opiant Pharmaceuticals.

* Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device * Reinforces Opiant’s continued commitment to innovative

In 2013, Opiant developed the … Agreementcombines Opiant’sopioid antagonist OPNT003 nasal nalmefene,with Aptar'sFDA-approved UnitDose System delivery device; Reinforces Opiant’s continued commitment to innovative overdose Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone.; The Phase 1 study in healthy volunteers will evaluate the effectiveness of 3mg nasal nalmefene compared to 4 mg nasal naloxone to reverse the respiratory depression produced SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 million from the National Institutes of Health’s (“NIH”) National Institute 2018-09-20 2021-03-09 SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail® (dodecyl maltoside), were published online in the Journal of Pharmacology and … Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene SANTA MONICA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021.

Jerome kern wife

Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in…

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are anticipated June 2021. Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to advance the clinical development of OPNT003, nasal nalmefene SANTA MONICA, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail® (dodecyl maltoside), were published online in the Journal of Pharmacology and … Opiant is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose and is working with Consort Medical to develop a delivery device for its OPNT003 (intranasal nalmefene), a long-lasting opioid antagonist for the treatment of opioid overdose. Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone.; The Phase 1 study in healthy volunteers will evaluate the effectiveness of 3mg nasal nalmefene compared to 4 mg nasal naloxone to reverse the respiratory depression produced 2021-03-09 SANTA MONICA, Calif., and HEMEL HEMPSTEAD, United Kingdom, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: O OPNT003 nasal nalmefene for opioid overdose - Opiant to use Aptar Pharma’s Unit Dose System- Upcoming FDA meeting in December to review Pharmacodynamic study in … SANTA MONICA, Calif., April 01, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 million from the National Institutes of Health’s (“NIH”) National Institute SANTA MONICA - Opiant Pharmaceuticals, Inc. ('Opiant') (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma ('Aptar'), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar's Unit Dose System (UDS) for the treatment of opioid overdose. The Aptar UDS has been approved by the U.S. Food and Drug Administration (FDA 2020-10-30 Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Aptar's FDA-approved Unit Dose System delivery device; Reinforces Opiant’s continued commitment to innovative overdose treatment options as America’s opioid epidemic worsens ; OPNT003 nasal nalmefene remains on track for NDA submission by the end of 2021; SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE Agreement combines Opiant’s opioid antagonist OPNT003 nasal nalmefene, with Apta r's FDA-approved Unit Dose System delivery device; Reinforces Opiant’s continued commitment to innovative overdose treatment options as America’s opioid epidemic worsens ; OPNT003 nasal nalmefene remains on track for NDA submission by the end of 2021; SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE “We thank BARDA for their ongoing support of OPNT003, nasal nalmefene,” said Roger Crystal, M.D., President and Chief Executive Officer of Opiant.

An intranasal formulation of nalmefene, a long-lasting opioid antagonist, designated as OPNT 003, is under development by Opiant Pharmaceuticals, for the

2018-09-10 · Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose 2021-04-05 · The Role of Science in Addressing the Opioid Crisis. N Engl J Med. 2017. 377:391-394 For Media and Investor Inquiries:Ben Atkins, Opiant(310) 598-5410batkins@opiant.com SANTA MONICA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit Dose System (UDS) for the treatment of opioid overdose. SANTA MONICA - Opiant Pharmaceuticals, Inc. ('Opiant') (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma ('Aptar'), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar's Unit Dose System (UDS) for the treatment of opioid overdose. Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program Based on FDA Feedback, Opiant Intends to Pursue 505 Development Pathway Opiant Anticipates Submitting an NDA for this Product Candidate in 2020 SANTA MONICA, Calif., Feb. 12, 2018 -- | April 10, 2021 Opiant Pharmaceuticals Inc (NASDAQ: OPNT) has dosed the first subjects in a head-to-head clinical study comparing the effectiveness of its investigational opioid antagonist nasal nalmefene (OPNT003) with nasal naloxone.

Nalmefene Nasal Spray. Opioid overdose. polygon Phase 3.